Siltuximab is currently approved in more than 40 countries worldwide for the treatment of all histopathologic subtypes of iMCD, a rare, life-threatening and debilitating orphan condition of the lymph nodes and related tissues.
The update is based on a 2020 publication which demonstrated that there is insufficient evidence to guide treatment based solely on lymph node histopathologic subtype.
Siltuximab is a monoclonal antibody that directly neutralises IL-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions.
Sylvant (siltuximab) is currently approved by the US Food and Drug Administration and the European Commission, as well as regulatory authorities in several other jurisdictions worldwide, for the treatment of adult patients with multicentric Castleman disease who are human immunodeficiency virus negative and human herpesvirus-8 (HHV-8) negative.
Indications and Usage See EMA Summary of Product Characteristics and FDA Prescribing Information or additional information.
Founded in March 2015, EUSA Pharma is a biopharmaceutical company focused on oncology and rare disease.
The company is headquartered in Hemel Hempstead, England, and has extensive commercial operations in the United States and Europe, alongside a direct presence in selected other markets across the globe.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007